Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its lead compound, TTI-101.

Read more: https://tvarditherapeutics.com/press/tvardis-tti-101-receives-5-million-in-funding-to-support-clinical-trials-and-translational-research/